This company has been marked as potentially delisted and may not be actively trading. Digirad (DRAD) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrendsBuy This Stock DRAD vs. NRXS, VRAYQ, VIVE, ELMD, QTI, ITRM, BMGL, MODD, OKUR, and PLURShould you be buying Digirad stock or one of its competitors? The main competitors of Digirad include NeurAxis (NRXS), ViewRay (VRAYQ), Viveve Medical (VIVE), Electromed (ELMD), QT Imaging (QTI), Iterum Therapeutics (ITRM), Basel Medical Group (BMGL), Modular Medical (MODD), OnKure Therapeutics (OKUR), and Pluri (PLUR). These companies are all part of the "medical" sector. Digirad vs. Its Competitors NeurAxis ViewRay Viveve Medical Electromed QT Imaging Iterum Therapeutics Basel Medical Group Modular Medical OnKure Therapeutics Pluri Digirad (NASDAQ:DRAD) and NeurAxis (NASDAQ:NRXS) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, media sentiment, valuation, institutional ownership, dividends, analyst recommendations, risk and earnings. Which has more volatility and risk, DRAD or NRXS? Digirad has a beta of 0.18, suggesting that its share price is 82% less volatile than the S&P 500. Comparatively, NeurAxis has a beta of 3.1, suggesting that its share price is 210% more volatile than the S&P 500. Does the media favor DRAD or NRXS? In the previous week, Digirad's average media sentiment score of 0.00 equaled NeurAxis'average media sentiment score. Company Overall Sentiment Digirad Neutral NeurAxis Neutral Do analysts prefer DRAD or NRXS? NeurAxis has a consensus target price of $7.00, suggesting a potential upside of 187.00%. Given NeurAxis' stronger consensus rating and higher possible upside, analysts plainly believe NeurAxis is more favorable than Digirad.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Digirad 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00NeurAxis 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is DRAD or NRXS more profitable? Digirad has a net margin of -5.32% compared to NeurAxis' net margin of -492.76%. NeurAxis' return on equity of 0.00% beat Digirad's return on equity.Company Net Margins Return on Equity Return on Assets Digirad-5.32% -3.75% -0.85% NeurAxis -492.76%N/A -641.25% Which has better valuation and earnings, DRAD or NRXS? Digirad has higher revenue and earnings than NeurAxis. Digirad is trading at a lower price-to-earnings ratio than NeurAxis, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioDigirad$114.18M0.09-$4.63M-$0.35-6.09NeurAxis$3.22M7.47-$14.63M-$0.99-2.46 Do insiders and institutionals hold more shares of DRAD or NRXS? 11.4% of Digirad shares are held by institutional investors. Comparatively, 11.8% of NeurAxis shares are held by institutional investors. 12.5% of Digirad shares are held by insiders. Comparatively, 26.4% of NeurAxis shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. SummaryNeurAxis beats Digirad on 8 of the 14 factors compared between the two stocks. Get Digirad News Delivered to You Automatically Sign up to receive the latest news and ratings for DRAD and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding DRAD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart DRAD vs. The Competition Export to ExcelMetricDigiradElectromedical Equipment IndustryMedical SectorNASDAQ ExchangeMarket Cap$10.14M$40.70M$5.75B$9.74BDividend Yield83.65%N/A3.95%4.03%P/E Ratio-0.683.6331.3826.41Price / Sales0.09209.59428.94154.89Price / Cash0.6941.3637.7559.42Price / Book0.212.6610.446.58Net Income-$4.63M-$2.66M$3.27B$265.92M Digirad Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)DRADDigiradN/A$2.13flatN/A-48.7%$10.14M$114.18M-0.68618High Trading VolumeNRXSNeurAxis2.6783 of 5 stars$2.36-4.8%$7.00+196.6%-19.0%$17.90M$3.22M-1.2819VRAYQViewRayN/AN/AN/AN/A$18K$102.21M0.00300VIVEViveve MedicalN/A$0.00flatN/AN/A$1K$6.83M0.0070ELMDElectromed2.5342 of 5 stars$19.16-2.7%$33.50+74.8%+61.8%$160.68M$61.44M25.55160Trending NewsAnalyst ForecastAnalyst RevisionQTIQT ImagingN/A$2.12+4.4%N/A+328.8%$57.52M$4.00M0.00N/ANews CoverageITRMIterum Therapeutics2.5936 of 5 stars$0.83-4.5%$9.00+983.3%-37.1%$38.85MN/A-0.9810Positive NewsBMGLBasel Medical GroupN/A$1.91-8.6%N/AN/A$38.57MN/A0.0036Positive NewsLockup ExpirationMODDModular Medical0.4373 of 5 stars$0.70-0.1%N/A-58.9%$38.03MN/A-1.3720News CoverageOKUROnKure Therapeutics2.9089 of 5 stars$2.74-2.1%$32.33+1,080.0%N/A$37.83MN/A-0.57N/ATrending NewsAnalyst ForecastAnalyst RevisionGap DownPLURPluri2.2184 of 5 stars$4.51-5.1%$12.00+166.1%-10.9%$37.39M$330K-0.82150Gap Down Related Companies and Tools Related Companies NeurAxis Competitors ViewRay Competitors Viveve Medical Competitors Electromed Competitors QT Imaging Competitors Iterum Therapeutics Competitors Basel Medical Group Competitors Modular Medical Competitors OnKure Therapeutics Competitors Pluri Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:DRAD) was last updated on 8/29/2025 by MarketBeat.com Staff From Our PartnersMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Digirad Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Digirad With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access